The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses results from recent research in this field. He discusses data from an old study showing that the TKI imatinib achieved better remission rates and is was more well tolerated than standard chemotherapy. Similarly, more recent studies have demonstrated that induction treatment with TKIs can almost eradicate the need for chemotherapy. Finally, Prof. Ottmann discusses the use of TKIs in the post-remission setting, where the data are less encouraging.